Special Issue

Immunity to Influenza Viruses

Message from the Guest Editors

Influenza viruses remain a constant global threat with a significant health and socioeconomic impact every year, and have the potential to cause devastating pandemics. Despite this, current vaccines against influenza viruses are only modestly effective, require annual reformulation, and may not provide protection against emerging influenza viruses from animal reservoirs. Therefore, new vaccines are needed to combat influenza viruses. The aim of this Special Issue on "Immunity to Influenza Viruses" is to explore the immune response to influenza A and B viruses from humans and animals. Original research and comprehensive review articles presenting recent progress, challenges, and future perspectives in influenza immunity and vaccines are invited. These may cover influenza virus–host interactions, innate immunity to influenza viruses, antiviral restriction, immune evasion mechanisms, antibody and B-cell responses to influenza viruses, T-cell-mediated immune responses to influenza viruses and vaccines against influenza viruses, as well as immune responses and vaccines in high-risk groups.

Guest Editors

Dr. Marios Koutsakos

Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3010, Australia

Dr. Sophie Valkenburg

Division of Public Health Laboratory Sciences, HKU Pasteur Research Pole, Hong Kong, China

Deadline for manuscript submissions

closed (31 March 2021)

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/52835

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/viruses

About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed
HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).